OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO
14:15 EDT 2 Jun 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company
developing novel therapeutics that target cancer stem cells (CSCs), or
tumor initiating cells, today highlighted new data presented this
afternoon in a post...
Other Sources for this Article
OncoMed Pharmaceuticals
Paul Hastings
President and Chief
Executive Officer
phastings@oncomed.com
William
D. Waddill, 650-995-8200
Senior Vice President, Chief Financial
Officer
william.waddill@oncomed.com
or
Media
Inquiries:
BCC Partners
Karen L. Bergman, 650-575-1509
kbergman@bccpartners.com
Michelle
Corral, 415-794-8662
mcorral@bccpartners.com
More From BioPortfolio on "OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
